Key result
12-month acarbose use is linked to lower arterial stiffness and vascular remodeling markers in T2D.
Why the study?
Does acarbose improve arterial stiffness in patients with type 2 diabetes mellitus?
Population
22 patients with type 2 diabetes mellitus
Design
Cohort
Follow-up
12 months
Authors
Loading...
May support vascular benefits of acarbose in T2DM; hypothesis-generating and should not change practice without RCTs.
Observational (n=22)
Does acarbose improve arterial stiffness in patients with type 2 diabetes mellitus?
Acarbose treatment for 12 months significantly improves arterial stiffness and reduces vascular remodeling markers in patients with type 2 diabetes mellitus.
Uzui et al. (2010) conducted an observational in type 2 diabetes mellitus (n=22). Acarbose was evaluated on Cardio-ankle vascular index (CAVI). Acarbose treatment for 12 months significantly reduced arterial stiffness (measured by CAVI) and vascular remodeling markers in patients with type 2 diabetes.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: